Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03872947
Title A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Toray Industries, Inc

stomach cancer


urinary bladder cancer

ovarian cancer

Advanced Solid Tumor

colon cancer


Pembrolizumab + TRK-950

Carboplatin + Gemcitabine + TRK-950

Imiquimod + TRK-950

Paclitaxel + Ramucirumab + TRK-950

Nivolumab + TRK-950

Cisplatin + Gemcitabine + TRK-950

Fluorouracil + Irinotecan + Leucovorin + TRK-950

Age Groups: adult | senior
Covered Countries USA | FRA

No variant requirements are available.